Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have been given an average rating of “Moderate Buy” by the six analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $6.8750.

Several research analysts have recently commented on the company. Alliance Global Partners started coverage on Sensus Healthcare in a report on Friday, March 6th. They issued a “buy” rating and a $7.50 price objective on the stock. Maxim Group dropped their target price on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Wall Street Zen lowered Sensus Healthcare from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research note on Thursday, January 22nd.

Sensus Healthcare Stock Performance

SRTS stock opened at $4.01 on Friday. The firm has a market cap of $66.01 million, a P/E ratio of -8.53 and a beta of 1.22. The firm’s fifty day moving average is $4.44 and its 200 day moving average is $3.96. Sensus Healthcare has a 52 week low of $3.03 and a 52 week high of $5.92.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.10). Sensus Healthcare had a negative return on equity of 15.11% and a negative net margin of 28.09%.The business had revenue of $4.94 million during the quarter, compared to the consensus estimate of $8.35 million. As a group, analysts forecast that Sensus Healthcare will post 0.32 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Pacific Ridge Capital Partners LLC raised its holdings in Sensus Healthcare by 21.8% during the 4th quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock valued at $2,781,000 after buying an additional 125,245 shares during the last quarter. Divisadero Street Capital Management LP increased its position in shares of Sensus Healthcare by 39.5% in the third quarter. Divisadero Street Capital Management LP now owns 452,897 shares of the company’s stock valued at $1,422,000 after acquiring an additional 128,224 shares during the period. Geode Capital Management LLC increased its position in shares of Sensus Healthcare by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 158,240 shares of the company’s stock valued at $630,000 after acquiring an additional 5,316 shares during the period. Sachetta LLC raised its stake in shares of Sensus Healthcare by 6.8% during the fourth quarter. Sachetta LLC now owns 148,508 shares of the company’s stock valued at $591,000 after acquiring an additional 9,500 shares during the last quarter. Finally, Greenline Wealth Management LLC purchased a new stake in shares of Sensus Healthcare during the fourth quarter worth about $513,000. 25.30% of the stock is owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.